Can you teach an old drug new tricks? Recent successes in repositioning existing drugs – from esketamine for treatment-resistant depression to remdesivir – originally developed to treat hepatitis C, tested for Ebola before being approved as a treatment for COVID 19 – point to potential upsides. The challenges, however, are many: from challenging IP prospects to skeptical investors. We have assembled an expert panel to discuss with us the enticing shortcuts repurposing may offer, the pitfalls it brings and how to develop strategies to overcome them.
Join us at the second virtual CTL@WCM Special Panel, where innovators, IP experts, and regulators gather to assess the landscape and talk about the opportunities.
Dr. Bruce Bloom, Chief Collaboration Officer, Healx
Eyal Barash, J.D., M.S, Founder Barash Law
Valentyna Chebanova, Sr. Manager of Business Development at Tarsus Pharmaceuticals
Moderated by Lisa Placanica, Senior Managing Director, Center for Technology Licensing at Weill Cornell Medicine